PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 16, 2025

Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047.

View Full Paper
Ask AI
Bookmark
Share

Authors

MRMeredith M. ReganPAPaolo A. AsciertoELEvan J. Lipson

Discussion

Loading...

Member takes

Overview

Analysis shows treatment-free survival improves with nivolumab plus relatlimab in advanced melanoma, suggesting benefits over monotherapy.

Key Points

  • At 48 months, mean treatment-free survival was 2.9 months longer with nivolumab plus relatlimab than with nivolumab alone.
  • Overall survival estimates at 48 months were 52% for nivolumab plus relatlimab and 43% for nivolumab monotherapy.
  • This observational analysis examined 714 patients in the phase 2/3 RELATIVITY-047 trial, comparing treatment groups for survival metrics.
  • Nivolumab plus relatlimab shows consistently longer treatment-free survival across various BRAF and PD-L1 status subgroups.

Cite This Study

Regan et al. (2025) studied this question.

synapsesocial.com/papers/68c93fe601120bef803baea3https://doi.org/10.1136/jitc-2025-012747
View Full Paper
Ask AI
Bookmark
Share